计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B127837-5mg |
5mg |
现货 ![]() |
| |
| B127837-25mg |
25mg |
现货 ![]() |
| |
| B127837-100mg |
100mg |
期货 ![]() |
|
| 英文别名 | 9H-purin-2-amine, 6-chloro-9-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)- | MFCD15528939 | BIIB 021 [WHO-DD] | NCGC00247877-01 | 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine | BIIB021,CNF2024 | DTXSID601025952 | SCHEMBL1791028 | H |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | BIIB021 |
| 生化机理 | 口服 BIIB021 可抑制 N87、BT474、CWR22、U87、SKOV3 和 Panc-1 等多种肿瘤异种移植模型中的肿瘤生长。在剂量为 120 毫克/千克时,BIIB021 能有效抑制 L540cy 肿瘤的生长。选择性 Hsp90 竞争性抑制剂(K i = 1.7 nM)对一系列 ATP 结合激酶或 Na + K + ATPase 没有明显活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 热休克蛋白 HSP90 抑制剂 |
| 备注 | 有关更多信息,请参阅SDS。有关溶解度,用法和处理的更多建议?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
BIIB021(CNF2024)是口服活性的HSP90抑制剂,Ki和EC50分别为1.7 nM和38 nM。A selective large conductance calcium activated potassium channel activator BIIB021 is an orally available, fully synthetic small-molecule inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively. |
| 纯度 | ≥98% |
| ALogP | 1.9 |
|---|
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine |
| INCHI | 1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20) |
| InChi Key | QULDDKSCVCJTPV-UHFFFAOYSA-N |
| Smiles | CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N |
| Isomeric SMILES | CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N |
| 分子量 | 318.77 |
| Reaxy-Rn | 11080986 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=11080986&ln= |
| 溶解性 | DMSO ≥60mg/mL Water <1.2mg/mL Ethanol ≥1.8mg/mL |
|---|---|
| 分子量 | 318.760 g/mol |
| XLogP3 | 1.900 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 318.1 Da |
| 单同位素质量Monoisotopic Mass | 318.1 Da |
| 拓扑极表面积Topological Polar Surface Area | 91.700 Ų |
| 重原子数Heavy Atom Count | 22 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 388.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | Warning |
| 1. Ernst JT, Liu M, Zuccola H, Neubert T, Beaumont K, Turnbull A, Kallel A, Vought B, Stamos D. (2014) Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.. Bioorg Med Chem Lett, 24 (1): (204-8). [PMID:24332488] |
| 2. Ye Liu, Jiaqi Liu, Renmei Zhang, Yan Guo, Hongbo Wang, Qingguo Meng, Yuan Sun, Zongliang Liu. (2019) Synthesis, Characterization, and Anticancer Activities Evaluation of Compounds Derived from 3,4-Dihydropyrimidin-2(1H)-one. MOLECULES, 24 (5): (891). [PMID:30832453] [10.3390/molecules24050891] |